173 filings
Page 2 of 9
SC TO-C
3344 ptl3yb76zw20zhn
6 Oct 20
Information about tender offer
4:05pm
SC TO-C
a0sqshd7 3vl
5 Oct 20
Information about tender offer
5:13pm
SC14D9C
oxft82hr3bx
5 Oct 20
Written communication relating to third party tender offer
4:43pm
SC14D9C
lwez0cjcyw9lq
5 Oct 20
Written communication relating to third party tender offer
7:01am
8-K
5agh35p539vu p208
5 Oct 20
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
6:47am
8-K
ei30qg4obzv
4 Aug 20
MyoKardia Reports Second Quarter 2020 Financial Results
4:38pm
8-K
4zgz1ug3
24 Jun 20
Submission of Matters to a Vote of Security Holders
4:11pm
8-K
xon05a1k
14 May 20
MyoKardia Announces Proposed Public Offering of Common Stock
5:24pm
424B5
07yvbn8f6qvb12u44ciw
14 May 20
Prospectus supplement for primary offering
5:18pm
424B5
wdf vg95y8avq
11 May 20
Prospectus supplement for primary offering
5:25pm
8-K
4ph7mhkr5usrwoj0d
11 May 20
Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs. Placebo
9:26am
8-K
bkpnsqvg1b q5f156qf
6 May 20
MyoKardia Reports First Quarter 2020 Financial Results
4:34pm
DEFA14A
wrio9ru8gcl
24 Apr 20
Additional proxy soliciting materials
4:27pm
DEFA14A
f3eco
24 Apr 20
Additional proxy soliciting materials
4:27pm
8-K
3as vbiu6j2ud
30 Mar 20
MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten
5:13pm
8-K
2ilc8l1 toy8nd4rs
26 Mar 20
MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic
8:46am
S-8
bq2jcwupcdh
27 Feb 20
Registration of securities for employees
5:02pm